NovaBay Pharmaceuticals Inc
NBY0.737USD
-0.023-3.00%
收盤 02/09, 16:00（美東）報價延遲15分鐘
694.01總市值
0.12本益比TTM
關於 NovaBay Pharmaceuticals Inc 公司
NovaBay Pharmaceuticals, Inc. is engaged in wound care products. The Company manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.
NovaBay Pharmaceuticals Inc簡介
公司代碼NBY
公司名稱NovaBay Pharmaceuticals Inc
上市日期Oct 26, 2007
CEOKazley (Michael John)
員工數量14
證券類型Ordinary Share
年結日Oct 26
公司地址2000 Powell St Ste 1150
城市EMERYVILLE
上市交易所NASDAQ OMX – NASDAQ Basic Amex
國家United States of America
郵編94608-1804
電話15108998800
網址https://novabay.com/
公司代碼NBY
上市日期Oct 26, 2007
CEOKazley (Michael John)
NovaBay Pharmaceuticals Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Ms. Swan Sit
Ms. Swan Sit
Independent Director
Independent Director
933.00
+841.00%
Mr. Justin M. Hall, Esq.
Mr. Justin M. Hall, Esq.
Vice President - Business Development, General Counsel, Corporate Secretary
Vice President - Business Development, General Counsel, Corporate Secretary
67.00
-513.00%
Mr. Paul E. Freiman, Ph.D.
Mr. Paul E. Freiman, Ph.D.
Director
Director
--
--
Dr. Yenyou (Jeff) Zheng, Ph.D.
Dr. Yenyou (Jeff) Zheng, Ph.D.
Independent Director
Independent Director
--
--
Mr. Tommy Law
Mr. Tommy Law
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
-26.00%
Capt. Jody Cain
Capt. Jody Cain
IR Contact Officer
IR Contact Officer
--
--
Mr. Michael Kazley
Mr. Michael Kazley
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
名稱
名稱/職務
職務
持股
持股變動
Ms. Swan Sit
Ms. Swan Sit
Independent Director
Independent Director
933.00
+841.00%
Mr. Justin M. Hall, Esq.
Mr. Justin M. Hall, Esq.
Vice President - Business Development, General Counsel, Corporate Secretary
Vice President - Business Development, General Counsel, Corporate Secretary
67.00
-513.00%
Mr. Paul E. Freiman, Ph.D.
Mr. Paul E. Freiman, Ph.D.
Director
Director
--
--
Dr. Yenyou (Jeff) Zheng, Ph.D.
Dr. Yenyou (Jeff) Zheng, Ph.D.
Independent Director
Independent Director
--
--
Mr. Tommy Law
Mr. Tommy Law
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
-26.00%
Capt. Jody Cain
Capt. Jody Cain
IR Contact Officer
IR Contact Officer
--
--
收入明細
FY2025Q3
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
由於公司未披露，未能獲取相關數據
地區USD
名稱
營收
佔比
United States
521.00K
0.00%
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 2月5日 週四
更新時間: 2月5日 週四
持股股東
股東類型
持股股東
持股股東
佔比
R01 Fund LP
45.02%
Framework Ventures Management LLC
45.02%
Lazar (David Elliot)
5.06%
The Vanguard Group, Inc.
1.45%
Poplar Point Capital Management LLC
0.81%
其他
2.63%
持股股東
持股股東
佔比
R01 Fund LP
45.02%
Framework Ventures Management LLC
45.02%
Lazar (David Elliot)
5.06%
The Vanguard Group, Inc.
1.45%
Poplar Point Capital Management LLC
0.81%
其他
2.63%
股東類型
持股股東
佔比
Corporation
90.04%
Individual Investor
5.07%
Investment Advisor
1.83%
Hedge Fund
0.81%
Investment Advisor/Hedge Fund
0.06%
Research Firm
0.01%
其他
2.18%
機構持股
更新時間: 1月1日 週四
更新時間: 1月1日 週四
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
41
3.14M
2.49%
+1.61M
2025Q3
38
1.37M
22.81%
-82.54K
2025Q2
43
1.43M
24.52%
+210.59K
2025Q1
42
1.34M
22.96%
+376.59K
2024Q4
40
546.91K
11.19%
+390.20K
2024Q3
42
126.44K
2.60%
+79.02K
2024Q2
44
12.01K
0.89%
-33.08K
2024Q1
44
12.73K
1.48%
-22.10K
2023Q4
45
34.29K
18.48%
+25.73K
2023Q3
47
15.18K
15.11%
-444.00
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
84.49K
0.07%
+84.22K
+31191.85%
Sep 30, 2025
Poplar Point Capital Management LLC
1.02M
0.81%
--
--
Oct 15, 2025
Geode Capital Management, L.L.C.
51.72K
0.04%
+17.90K
+52.92%
Sep 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
除權除息日
類型
比率
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Nov 14, 2022
Merger
35→1
Nov 14, 2022
Merger
35→1
公告日期
除權除息日
類型
比率
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Nov 14, 2022
Merger
35→1
Nov 14, 2022
Merger
35→1
Nov 14, 2022
Merger
35→1
Nov 14, 2022
Merger
35→1
